1. Ultra Short Course Chemotherapy for Early-Stage Non-Hodgkin’s Lymphoma in Children
- Author
-
Elisabetta Schiavello, Filippo Spreafico, Francesco Barretta, Giulia Meraviglia, Veronica Biassoni, Monica Terenziani, Luna Boschetti, Giovanna Gattuso, Stefano Chiaravalli, Luca Bergamaschi, Nadia Puma, Giovanna Sironi, Olga Nigro, Marta Podda, Cristina Meazza, Michela Casanova, Andrea Ferrari, Roberto Luksch, and Maura Massimino
- Subjects
non-Hodgkin lymphoma ,early-stage ,chemotherapy ,late-effects ,intrathecal ,maintenance ,Pediatrics ,RJ1-570 - Abstract
Early-stage non-Hodgkin’s lymphomas (ES-NHL) are associated with high survival rates. To minimize the risk of long-term sequelae, the duration and intensity of chemotherapy have been progressively reduced. Between 1988 and 2018, children with ES-NHL were treated at a single institute with two subsequent protocols. Protocol I consisted of a 7-week induction phase followed by a maintenance phase alternating 6-mercaptopurine plus MTX, a brief reinduction, and thioguanine plus cytosine arabinoside, for a total duration of 8 months. The subsequent protocol II (applied since 1997) was modified adding etoposide plus a further dose of HD-MTX and omitting maintenance in all histological subtypes except T-lymphoblastic lymphoma (T-LBL), for a total duration of 9 weeks. Intrathecal prophylaxis was not provided in either protocol. With a median follow-up of 98.4 months, the 5-year event-free survival (EFS) rates in protocol I (n = 21) and II (n = 25) were 76.2% and 96%, respectively, and the 5-year overall survival (OS) rates were 90.5% and 96%, respectively. None of the patients experienced disease progression or relapse within the central nervous system (CNS). Acute toxicity was manageable in both protocols, except for a case of presumed acute cardiotoxic death; no chronic sequelae were evident. Low-intensity chemotherapy for 9 weeks without intrathecal prophylaxis was sufficient for curing children with ES-NHL, without jeopardizing the excellent survival rate of this disease.
- Published
- 2022
- Full Text
- View/download PDF